C occidioidomycosis is a well-known infection in the southwestern US (1, 2) that has become more frequent in endemic areas, with an increase from 5.3 new cases per 100,000 persons in 1998 to 42.6 new cases per 100,000 in 2011 (3) . Th e increase is likely infl uenced by population migration, an increased number of immunosuppressed patients, and increased awareness of the disease (1, 2, 4) . Pulmonary disease is the most common presentation of coccidioidomycosis. Most cases are asymptomatic or resolve spontaneously, but some patients with diverse risk factors may develop severe disease. Diff use miliary pneumonia is uncommon, and it is usually found in immunocompromised patients, in whom it has a poor prognosis (1, 4, 5, 6) .
CASE DESCRIPTION
A previously healthy 49-year-old black man was sent from a prison unit to the emergency center. He presented with 2 weeks of new-onset progressive dyspnea associated with dry cough and intermittent fevers and chills. His blood pressure was 124/75 mm Hg; temperature, 97.5°F; heart rate, 105 beats/minute; and respiration, 28 breaths/minute with an oxygen saturation of 86% on room air. His body mass index was 20.4 kg/m². He was in moderate respiratory distress and had bilateral fi ne crackles. His leukocyte count was 12.4 K/μL with neutrophil predominance and eosinophilia of 1.4 K/μL. Chest radiography and computed tomography of the chest are shown in Figure 1 . Th e patient was given ceftriaxone and azithromycin but his fever and hypoxemia persisted, and fl uconazole was started on the third day of hospitalization.
Additional laboratory tests were obtained to evaluate for atypical pneumonia (Table 1) . A transbronchial biopsy showed loose granulomas with moderate chronic and mild acute infl ammation and occasional spherules with interstitial fi brosis. Bronchial washing cultures were positive for Coccidioides immitis per DNA probe. He was discharged on oral fl uconazole 400 mg daily and supplemental oxygen. Approximately 1 month later, he no longer required oxygen supplementation (with an oxygen saturation of 94% on room air), and it was recommended he complete 1 year of antifungal therapy.
DISCUSSION
Coccidioides sp., a dimorphic fungus present in the soil as a mold, is found only in the Western hemisphere and is endemic in the southwestern US, northern Mexico, and South America. Arthroconidia disperse into the air and can be inhaled by animals or humans. Within the human body, they transform into spherical structures called spherules that eventually grow and break open, releasing hundreds to thousands of endospores, which perpetuate the cycle. Endospores may spread via hematogenous and/or lymphatic drainage (1, 4) . Two species have been described: C. immitis (which seems to be limited to the San Joaquin Valley) and C. posadasii (2, 4) .
One-half to two-thirds of these infections are asymptomatic or subclinical (4, 5) . Individuals older than 60 years and patients with congestive heart failure, chronic lung disease, cancer, AIDS, or other immunocompromised states are prone to symptomatic disease (5). Immunosuppressed patients, pregnant women in the third trimester, persons of Filipino or African American ancestry, diabetics, the elderly, and smokers are at increased risk for severe or disseminated disease (4, 6) . Th is disease has fi ve main clinical presentations: acute pneumonia, chronic progressive fi brocavitary pneumonia, pulmonary nodules and cavities, extrapulmonary nonmeningeal disease, and meningitis (1). Pulmonary disease is seen in almost 95% of cases (4, 6) .
Acute pneumonia is an acute respiratory infection that usually occurs 1 to 3 weeks after exposure (1, 5) and can be associated with generalized symptoms and/or cutaneous manifestations (1, 4) . Th e chest x-rays of patients with acute pneumonia are similar to those for other etiologies of community-acquired pneumonia (1, 4) . Coccidioidomycosis can account for 17% to 29% of cases of community-acquired pneumonia in endemic areas (3) . Residents and recent travelers to endemic areas with compatible symptoms should be evaluated for coccidioidomycosis (5) .
Diff use miliary pneumonia is uncommon and presents as bilateral reticulonodular or miliary infi ltrates on imaging studies. It can be associated with large inoculums, fungemia, or lymphatic spread. Th e presence of diff use miliary pneumonia suggests underlying immunodefi ciency, and those patients are usually critically ill, with the vast majority developing acute respiratory distress syndrome (ARDS) (1, 4, 5) . ARDS has a mortality of nearly 100% in immunosuppressed patients (4, 6) . Miliary disease in immunocompetent patients is very rare. Th e largest series of immunocompetent patients with diff use miliary pneumonia reported 8 patients, 2 of whom were pregnant; 5 (62.5%) developed ARDS, and 3 (37.5%) died (7) .
Diagnosis is usually made with serology, culture, or biopsy (4). All cultures should be confi rmed with DNA probe technology (6) . Th e fi nding of spherules in any body fl uid or tissue is always indicative of infection. Serologic testing is based on fi nding antibodies to a coccidioidal-related antigen. Diagnosis is also based on immunologic evidence of disease in the form of detection of IgM or IgG by immunodiff usion, enzyme immunoassay, latex agglutination, tube precipitin, or complement fi xation (8, 9) . Skin testing (coccidioidin) cannot diff erentiate between recent or past infection (10) .
Most pulmonary infections are self-limited and do not require treatment. Treatment should be considered for patients at high risk for severe disease (1, (4) (5) (6) . Itraconazole and fl uconazole are the most commonly used drugs (1, 5) . Galgiani et al compared fl uconazole to itraconazole in a randomized controlled trial and found that itraconazole had better outcomes (11) . Fluconazole has excellent bioavailability and tissue penetration and few drug interactions, making it the agent of choice (4). Treatment is usually given for 3 to 6 months for acute pneumonia (1, 4, 5) . Diff use miliary pneumonia may require several weeks of amphotericin B, followed by maintenance therapy with an azole for a year or indefi nitely (4, 6). 
